Your browser doesn't support javascript.
loading
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.
Campbell, Katie M; Amouzgar, Meelad; Pfeiffer, Shannon M; Howes, Timothy R; Medina, Egmidio; Travers, Michael; Steiner, Gabriela; Weber, Jeffrey S; Wolchok, Jedd D; Larkin, James; Hodi, F Stephen; Boffo, Silvia; Salvador, Lisa; Tenney, Daniel; Tang, Tracy; Thompson, Marshall A; Spencer, Christine N; Wells, Daniel K; Ribas, Antoni.
Afiliação
  • Campbell KM; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: katiecampbell@mednet.ucla.edu.
  • Amouzgar M; Department of Pathology, Stanford University, Stanford, CA 94305, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
  • Pfeiffer SM; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
  • Howes TR; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
  • Medina E; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • Travers M; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
  • Steiner G; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
  • Weber JS; Perlmutter Cancer Center, NYU School of Medicine, New York, NY 10016, USA.
  • Wolchok JD; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medicine, New York
  • Larkin J; Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.
  • Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Boffo S; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA.
  • Salvador L; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA.
  • Tenney D; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA.
  • Tang T; Bristol Myers Squibb Corp., Princeton, NJ 08540, USA.
  • Thompson MA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
  • Spencer CN; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
  • Wells DK; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
  • Ribas A; Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, C
Cancer Cell ; 41(4): 791-806.e4, 2023 04 10.
Article em En | MEDLINE | ID: mdl-37037616
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Idioma: En Ano de publicação: 2023 Tipo de documento: Article